J0742 Injection imip 4 cilas 4 releb 2mg
Also known as: imipenem/cilastatin/relebactam, Recarbrio, carbapenem/inhibitor combo
Imipenem, cilastatin, and relebactam combination injection, an antibiotic combination with beta-lactamase inhibitor for multidrug-resistant gram-negative infections.
In Plain Language
advanced antibiotic for resistant bacteria; serious multidrug-resistant infection treatment
Clinical Context
Triple combination including carbapenem with renal dehydropeptidase inhibitor and novel beta-lactamase inhibitor for extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) resistant organisms.
RVU Information
CPT J0742 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J0742?
CPT J0742 (Injection imip 4 cilas 4 releb 2mg) is a J Codes (Drugs) code. Imipenem, cilastatin, and relebactam combination injection, an antibiotic combination with beta-lactamase inhibitor for multidrug-resistant gram-negative infections.
How is J0742 administered?
CPT J0742 is administered by a healthcare provider, typically via injection or infusion. Triple combination including carbapenem with renal dehydropeptidase inhibitor and novel beta-lactamase inhibitor for extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) resistant organisms. It is used by infectious disease, critical care, hospital medicine.
When is CPT J0742 used?
Triple combination including carbapenem with renal dehydropeptidase inhibitor and novel beta-lactamase inhibitor for extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) resistant organisms.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.